Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, July 5, 2017

Learn more about research on the immune system in MS

Click here to receive MS news via e-mail

Understanding and stopping MS in its tracks requires a better understanding of the role that the immune system plays in this disease. This system is involved both in the inflammatory attacks on myelin and, very possibly, in the injury to axons (the wire-like nerve fibers) that contributes to longer-term disability. Research on the immune system includes studies on:
  • Understanding components of the immune system such as T cells, B cells, and antibodies
  • Identifying new targets for therapeutic intervention while leaving the rest of the immune system capable of fighting infections
  • Identifying substances and processes involved in the injury of axons
  • Identifying the body’s natural immune messenger molecules that can either turn on or turn off immune attacks
Significant progress is being made in understanding the immune system's involvement in MS, which will help drive breakthrough solutions to change the world for everyone with MS. 

We’re making progress

Studies of the immune system in MS laid the groundwork for every disease-modifying therapy now available, and these studies continue to hold promise for finding ways to stop MS. Here are reports of recent progress:

Decades of Basic Research Pay Off with Early Clinical Trial of Immune Therapy 
An international team has reported results of a small, early clinical trial involving 10 people with relapsing or secondary-progressive MS. The trial tested the feasibility and safety of using a patient’s own altered blood cells to reduce immune responses against specific components of myelin, the nerve covering that is a key target of immune attacks in MS. Treatment appeared safe and showed signs of reducing immune responses to myelin, This is one example of how the Society’s long-term investment in basic research that has relevance to MS pays off. Read details here.
Immune system may drive cognitive changes in MS
Memory impairment and other cognitive changes are experienced by many people with MS, but the details of how this occurs are not clear. Now researchers supported in part by the National MS Society report evidence that a group of immune system proteins called “complement” may play a role in the loss of nerve connections (synapses) in the hippocampus, a part of the brain linked to memory. Read more
Distinguishing between 'good' and 'bad' immune cells
A team funded by the National MS Society has shed new light on immune cells known as macrophages, and how one type of these cells may play a significant role in launching damage in MS. The researchers have discovered a way to differentiate between good and bad types of these immune cells active during MS-like disease in mice, and if further research shows that these findings hold true for people with MS, this opens up possibilities for developing therapies that target the bad cells and spare the good cells. Read more

          MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: 

No comments: